Sustainable rare diseases business and drug access: no time for misconceptions
Open Access
- 1 January 2013
- journal article
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 8 (1), 109
- https://doi.org/10.1186/1750-1172-8-109
Abstract
Legislative incentives enacted in Europe through the Regulation (EC) No. 141/2000 to incentivize orphan drug development have over the last 12 years constituted a powerful impetus toward R&D directed at the rare diseases population.Keywords
This publication has 21 references indexed in Scilit:
- Orphan drug development: an economically viable strategy for biopharma R&DDrug Discovery Today, 2012
- Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?Orphanet Journal of Rare Diseases, 2012
- Estimating the budget impact of orphan medicines in Europe: 2010 - 2020Orphanet Journal of Rare Diseases, 2011
- What principles should govern the use of managed entry agreements?International Journal of Technology Assessment in Health Care, 2011
- Rare diseases, orphan drugs and their regulation: questions and misconceptionsNature Reviews Drug Discovery, 2010
- A comparative study of European rare disease and orphan drug marketsHealth Policy, 2010
- Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturersHealth Policy, 2010
- Why rare diseases are an important medical and social issueThe Lancet, 2008
- The cost of biopharmaceutical R&D: is biotech different?Managerial and Decision Economics, 2007
- Productivity in pharmaceutical–biotechnology R&D: the role of experience and alliancesJournal of Health Economics, 2005